Dr. Lal PathLabs Limited (IN:LALPATHLAB)
:LALPATHLAB
Want to see IN:LALPATHLAB full AI Analyst Report?
LALPATHLAB Stock Chart & Stats
₹1472.95
-₹106.10(-3.42%)
At close: 4:00 PM EST
₹1472.95
-₹106.10(-3.42%)
Day’s Range― - ―
52-Week Range₹1,272.00 - ₹1,771.30
Previous CloseN/A
Volume152.98K
Average Volume (3M)3.61K
Market Cap
₹279.63B
Enterprise Value₹271.51B
Total Cash (Recent Filing)₹13.02B
Total Debt (Recent Filing)₹2.55B
Price to Earnings (P/E)41.7
Beta0.58
Next Earnings
Jul 23, 2026EPS Estimate
8.62Next Dividend Ex-DateN/A
Dividend Yield0.89%
Share Statistics
EPS (TTM)32.04
Shares Outstanding167,637,770
10 Day Avg. Volume2,182
30 Day Avg. Volume3,614
Financial Highlights & Ratios
PEG Ratio12.69
Price to Book (P/B)8.73
Price to Sales (P/S)7.93
P/FCF Ratio40.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)35.26
Revenue Forecast (FY)₹31.26B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetA low debt-to-equity ratio (~0.08 in FY2026) and a meaningful reduction from ~0.25 in FY2023 provide lasting financial flexibility. This conservative leverage profile supports capex and network expansion, cushions downturns, lowers refinancing risk, and underpins long-term resilience.
Strong Operating Cash FlowOperating cash flow of 7.0B in FY2026 and coverage of net income (~1.56x) indicates durable cash generation and earnings quality. Reliable OCF funds lab maintenance and measured expansion, reduces reliance on external funding, and supports sustainable capital allocation over months to years.
Resilient Revenue TrendConsistent multi-year revenue growth (roughly 10% in FY2024/25 and ~6% in FY2026) reflects steady demand for diagnostics and diversified B2C/B2B channels. That recurring volume across a wide lab/collection network sustains scale economies and a stable revenue base over the medium term.
Bears Say
Margin Compression RiskA sharp decline in gross margin and a dip in net margin in FY2026 point to structural cost or pricing pressures. If sustained, margin erosion will reduce operating leverage and cash available for reinvestment, weakening long-term profitability and returns unless addressed by cost or pricing actions.
Weaker FCF Conversion & VolatilityFree cash flow conversion weakened to ~76% of net income in FY2026 from ~92% in FY2025, and historical negative FCF in FY2022 highlights volatility. Material swings from working capital and capex cycles raise execution and financing risk for sustained network investments or distributions.
Slowing Top-line GrowthRevenue growth decelerated to ~6% in FY2026 from ~10% previously, suggesting market saturation or competitive pressure. Slower top-line expansion can limit operating-leverage gains, constrain margin recovery and reduce the pace at which the company can scale its lab and collection footprint profitably.
Dr. Lal PathLabs Limited News
LALPATHLAB FAQ
What was Dr. Lal PathLabs Limited’s price range in the past 12 months?
Dr. Lal PathLabs Limited lowest stock price was ₹1272.00 and its highest was ₹1771.30 in the past 12 months.
What is Dr. Lal PathLabs Limited’s market cap?
Dr. Lal PathLabs Limited’s market cap is ₹279.63B.
When is Dr. Lal PathLabs Limited’s upcoming earnings report date?
Dr. Lal PathLabs Limited’s upcoming earnings report date is Jul 23, 2026 which is in 63 days.
How were Dr. Lal PathLabs Limited’s earnings last quarter?
Dr. Lal PathLabs Limited released its earnings results on Apr 30, 2026. The company reported ₹7.865 earnings per share for the quarter, beating the consensus estimate of ₹7.247 by ₹0.618.
Is Dr. Lal PathLabs Limited overvalued?
According to Wall Street analysts Dr. Lal PathLabs Limited’s price is currently Overvalued.
Does Dr. Lal PathLabs Limited pay dividends?
Dr. Lal PathLabs Limited pays a Quarterly dividend of ₹7 which represents an annual dividend yield of 0.89%. See more information on Dr. Lal PathLabs Limited dividends here
What is Dr. Lal PathLabs Limited’s EPS estimate?
Dr. Lal PathLabs Limited’s EPS estimate is 8.62.
How many shares outstanding does Dr. Lal PathLabs Limited have?
Dr. Lal PathLabs Limited has 167,637,770 shares outstanding.
What happened to Dr. Lal PathLabs Limited’s price movement after its last earnings report?
Dr. Lal PathLabs Limited reported an EPS of ₹7.865 in its last earnings report, beating expectations of ₹7.247. Following the earnings report the stock price went down -2.104%.
Which hedge fund is a major shareholder of Dr. Lal PathLabs Limited?
Currently, no hedge funds are holding shares in IN:LALPATHLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Dr. Lal PathLabs Limited
Dr. Lal PathLabs Limited provides diagnostic and related healthcare tests and services in India and internationally. It operates laboratories for carrying the pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. The company also offers lab staff training; technical; and lab management services. As of March 31, 2022, the company had 277 clinical laboratories, including National Reference Lab at Delhi and Regional Reference Lab at Kolkata; and 4,731 patient service centers and 10,599 pick-up points. Dr. Lal PathLabs Limited was founded in 1949 and is based in Gurugram, India.
Technical Analysis
Krsnaa Diagnostics Limited
―
Metropolis Healthcare Ltd.
―
Thyrocare Technologies Ltd
―
Vijaya Diagnostic Centre Ltd.
―
Vimta Labs Limited
―